170 related articles for article (PubMed ID: 22336886)
1. Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer.
Campbell TJ; Tindall DJ; Figg WD
Cancer Biol Ther; 2012 Mar; 13(5):237-8. PubMed ID: 22336886
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.
Chang KH; Li R; Papari-Zareei M; Watumull L; Zhao YD; Auchus RJ; Sharifi N
Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13728-33. PubMed ID: 21795608
[TBL] [Abstract][Full Text] [Related]
3. The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.
Sharifi N
J Investig Med; 2012 Feb; 60(2):504-7. PubMed ID: 22064602
[TBL] [Abstract][Full Text] [Related]
4. Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues.
Dai C; Chung YM; Kovac E; Zhu Z; Li J; Magi-Galluzzi C; Stephenson AJ; Klein EA; Sharifi N
Clin Cancer Res; 2017 Oct; 23(20):6351-6362. PubMed ID: 28733443
[No Abstract] [Full Text] [Related]
5. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
[TBL] [Abstract][Full Text] [Related]
6. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
7. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
[TBL] [Abstract][Full Text] [Related]
8. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
9. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
[TBL] [Abstract][Full Text] [Related]
10. Basis for hormonal management of advanced prostate cancer.
Geller J
Cancer; 1993 Feb; 71(3 Suppl):1039-45. PubMed ID: 7679038
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.
Cai C; Balk SP
Endocr Relat Cancer; 2011 Oct; 18(5):R175-82. PubMed ID: 21712345
[TBL] [Abstract][Full Text] [Related]
13. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer.
Mohler JL; Titus MA; Bai S; Kennerley BJ; Lih FB; Tomer KB; Wilson EM
Cancer Res; 2011 Feb; 71(4):1486-96. PubMed ID: 21303972
[TBL] [Abstract][Full Text] [Related]
14. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.
Montgomery B; Nelson PS; Vessella R; Kalhorn T; Hess D; Corey E
BMC Cancer; 2010 May; 10():244. PubMed ID: 20509933
[TBL] [Abstract][Full Text] [Related]
15. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo.
Ming DS; Pham S; Deb S; Chin MY; Kharmate G; Adomat H; Beheshti EH; Locke J; Guns ET
J Steroid Biochem Mol Biol; 2014 Sep; 143():19-28. PubMed ID: 24565566
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
Taplin ME; Manola J; Oh WK; Kantoff PW; Bubley GJ; Smith M; Barb D; Mantzoros C; Gelmann EP; Balk SP
BJU Int; 2008 May; 101(9):1084-9. PubMed ID: 18399827
[TBL] [Abstract][Full Text] [Related]
17. "Getting from here to there"--mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer.
Sharifi N; McPhaul MJ; Auchus RJ
J Investig Med; 2010 Dec; 58(8):938-44. PubMed ID: 21030877
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer androgen biosynthesis relies solely on CYP17A1 downstream metabolites.
Snaterse G; Taylor AE; Moll JM; O'Neil DM; Teubel WJ; van Weerden WM; Arlt W; Hofland J
J Steroid Biochem Mol Biol; 2024 Feb; 236():106446. PubMed ID: 38104728
[TBL] [Abstract][Full Text] [Related]
19. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
20. Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency.
Geller J; Albert J; de la Vega D; Loza D; Stoeltzing W
Cancer Res; 1978 Nov; 38(11 Pt 2):4349-52. PubMed ID: 81107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
